Business Expanding Sanofi, a French pharmaceutical company, boosts its investment in SSP Narita Plant
Oct 12, 2022
SSP Co., Ltd. is a pharmaceutical company specializing in OTC (over-the-counter) drugs and healthcare products and is part of the Consumer Healthcare business of the Sanofi Group , a pharmaceutical company based in Paris, France. Sanofi is one of the world's largest pharmaceutical companies, with approximately 100,000 employees from 146 nationalities working to create and deliver healthcare solutions in about 100 countries. In Japan, the company has a wide range of business activities, including the provision of ethical drugs for immunological diseases, congenital and rare diseases, oncology, diabetes, and cardiovascular diseases, as well as vaccines and self-care solutions.
- Biotechnology & Lifescience
SSP has been providing a variety of products to meet health needs for over 250 years since its establishment in 1765. In 2001, the company became part of Boehringer Ingelheim, a German pharmaceutical manufacturer, and in 2010, it became a wholly owned subsidiary of Boehringer Ingelheim. Then in 2017, following a business exchange between Boehringer Ingelheim and Sanofi, it became a member of the Sanofi Group.
Since then, Sanofi has made major reinvestments to build a new warehouse with full automation and install the latest tableting equipment (equipment to produce tablets by compressing a mixture of pharmaceuticals and additives or their granules, etc.) and quality inspection equipment using image recognition technology at the SSP Narita Plant. In October 2022, construction was completed on a new pharmaceutical formulation facility that enables granulation and dispensing using state-of-the-art technology. Through the introduction of advanced technologies, the company will achieve sophistication in the manufacturing processes and reduce environmental impact, thereby demonstrating technological leadership in the pharmaceutical industry.
New pharmaceutical formulation facility at SSP Narita Plant
Upon the Sanofi's reinvestment in the SSP Narita Plant, JETRO Chiba, together with JETRO’s Invest Japan Business Support Center (IBSC), provided tax consultation and information on incentives, arranged meetings with local governments, and supported discussions for the establishment of a new incentive scheme.
JETRO supports your business in Japan
JETRO IBSCs are located in Japan's major business hubs and provide one-stop support and service to foreign firms seeking to set up or expand business in Japan. The centers, which provide free temporary office space, consultation with expert advisors and access to a wealth of business information, tailor support according to the specific needs and phase of development of each firm.